Keith Holliday - STAAR Surgical Vice President - Research & Development
| STAA Stock | USD 17.72 0.20 1.12% |
President
Dr. Keith Holliday, Ph.D. serves as Chief Technology Officer of the Company. Dr. Keith Holliday joined STAAR in August 2015 as Vice President of Research and Development. In March 2017, he assumed the role of the Chief Technology Officer. From 2007 to his arrival at STAAR, he served as Vice President, Research and Development at ReVision Optics where he oversaw the development of their corneal inlay technology that includes a hydrogel inlay for presbyopia correction, delivery devices and clinical methodologies as well as managing firstinman clinical studies. Previously, he was Director of Laser Technology at Advanced Medical Optics and Staff Laser Scientist at VISX. Prior to joining VISX, Dr. Holliday worked primarily in academia. He obtained his first degree in Physics and Electronics from the University of Saint Andrews in Scotland and a Ph.D. from the Laser Physics Centre at the Australian National University. He spent three years at the Swiss Federal Institute of Technology, where he was primarily involved with the utilization of optically active polymers and crystals, to develop materials and techniques for very high density, holographic optical storage and computational systems. Dr. Holliday holds patents in excimer laser beam detection, control and profiling, and methods to correct presbyopia that synergistically take into account the epitheliums response to corneal inlays, and he has also authored 37 peer reviewed publications in the scientific literature plus two book chapters and one singleauthored book. He is considered an expert on presbyopia and served as a committee member for the International Society of Presbyopia. since 2017.
| Age | 62 |
| Tenure | 8 years |
| Address | 25510 Commercentre Drive, Lake Forest, CA, United States, 92630 |
| Phone | 626 303 7902 |
| Web | https://www.staar.com |
STAAR Surgical Management Efficiency
The company has return on total asset (ROA) of (0.0155) % which means that it has lost $0.0155 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0516) %, meaning that it created substantial loss on money invested by shareholders. STAAR Surgical's management efficiency ratios could be used to measure how well STAAR Surgical manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.08. The current year's Return On Capital Employed is expected to grow to 0.12. At present, STAAR Surgical's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 148.7 M, whereas Intangible Assets are forecasted to decline to about 147.9 K.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Aileen RuffPatry | West Pharmaceutical Services | N/A | |
| Agostino Ricupati | The Cooper Companies, | 57 | |
| Robert Douglas | ResMed Inc | 64 | |
| Patrik Eriksson | Envista Holdings Corp | 56 | |
| Simon Campion | Becton Dickinson and | 49 | |
| Annette Favorite | West Pharmaceutical Services | 60 | |
| Jacqueline Scanlan | Haemonetics | 46 | |
| Robert Auerbach | The Cooper Companies, | 58 | |
| Brian Andrews | The Cooper Companies, | 45 | |
| James Lim | Becton Dickinson and | 56 | |
| Patrick Kaltenbach | Becton Dickinson and | 56 | |
| Stewart Strong | Haemonetics | 58 | |
| Bobby Ghoshal | ResMed Inc | 52 | |
| Holly Sheffield | The Cooper Companies, | 54 | |
| Alberto Mas | Becton Dickinson and | 59 | |
| Howard Yu | Envista Holdings Corp | 51 | |
| Olivier Loeillot | Repligen | 55 | |
| John DeFord | Becton Dickinson and | 55 | |
| Roland Goette | Becton Dickinson and | 58 | |
| Bernard Birkett | West Pharmaceutical Services | 56 | |
| Don OCallaghan | West Pharmaceutical Services | N/A | |
Management Performance
| Return On Equity | -0.0516 | ||||
| Return On Asset | -0.0155 |
STAAR Surgical Leadership Team
Elected by the shareholders, the STAAR Surgical's board of directors comprises two types of representatives: STAAR Surgical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of STAAR. The board's role is to monitor STAAR Surgical's management team and ensure that shareholders' interests are well served. STAAR Surgical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, STAAR Surgical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nancy Sabin, Chief Officer | ||
| Brian Moore, IR Contact Officer | ||
| Warren Foust, Chief Officer | ||
| HansMartin Blickensdoerfer, President International Commercial Operations | ||
| Thomas Frinzi, CEO President | ||
| Samuel Gesten, Vice President General Counsel, Corporate Compliance Officer and Secretary | ||
| Caren Mason, CEO and President Director and Chairman of Quality and Regulatory Committee | ||
| Joanne Egamino, Global Operations | ||
| Patrick Williams, Chief Officer | ||
| Robert Studholme, Senior Operations | ||
| Stephen CFA, CEO President | ||
| James Francese, VP of Global Marketing | ||
| Keith Holliday, Vice President - Research & Development | ||
| Scott MD, Chief Officer | ||
| Nathaniel Esq, General Secretary | ||
| Magda Michna, Regulatory Clinical | ||
| Philippe Subrin, Vice President - Switzerland Operations |
STAAR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is STAAR Surgical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0516 | ||||
| Return On Asset | -0.0155 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | (0.57) % | ||||
| Current Valuation | 692.16 M | ||||
| Shares Outstanding | 49.33 M | ||||
| Shares Owned By Insiders | 0.55 % | ||||
| Shares Owned By Institutions | 99.45 % | ||||
| Number Of Shares Shorted | 4.35 M | ||||
| Price To Earning | 460.83 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether STAAR Surgical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of STAAR Surgical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Staar Surgical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Staar Surgical Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in STAAR Surgical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade STAAR Stock refer to our How to Trade STAAR Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of STAAR Surgical. If investors know STAAR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about STAAR Surgical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.018 | Earnings Share (0.41) | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets |
The market value of STAAR Surgical is measured differently than its book value, which is the value of STAAR that is recorded on the company's balance sheet. Investors also form their own opinion of STAAR Surgical's value that differs from its market value or its book value, called intrinsic value, which is STAAR Surgical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because STAAR Surgical's market value can be influenced by many factors that don't directly affect STAAR Surgical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between STAAR Surgical's value and its price as these two are different measures arrived at by different means. Investors typically determine if STAAR Surgical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, STAAR Surgical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.